![22411298](https://user-images.githubusercontent.com/22411298/83390080-dfd50b00-a40e-11ea-9aea-08e2204eecc7.png)
## Atanu Bhattacharjee,Ph.D (Statistics)
Assistant Professor Biostatistics
Centre for Cancer Epidemiology, Tata Memorial Centre, India

## Biography
I am working as Assistant Professor Biostatistics in the Section of Biostatistics, Centre for Cancer Epidemiology, Tata Memorial Centre, Mumbai.I am also an Ajunct Professor of Statistics at Department of Applied Mathematics, Indian Institute of Technology-Dhanbad. I completed by Ph.D in statistics under the supervision of Dr. Dilip C Nath.
My research interests include Bayesian inference, longitudinal data analysis, survival analysis, gene expression data analysis.
## Research Paper
### [2020]
1. Abin Thomas,Gajendra K.Vishwakarma and Atanu Bhattacharjee.Joint modeling of longitudinal and time-to-event data on multivariate protein biomarkers.https://doi.org/10.1016/j.cam.2020.113016.

2.Atanu Bhattacharjee,Subita Patil,Sanjay Talole,Arjun Singh,Pankaj Chaturvedie,Rajesh Dikshit.An impact of single prevalence rate reduction of tobacco on cancer incidence- A challenge for global policy maker.https://doi.org/10.1016/j.cegh.2020.04.029.[pagination_CEGH_583.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4714852/pagination_CEGH_583.pdf).

3. Vijay M. Patil  Arti Bhelekar  Nandini Menon  Atanu Bhattacharjee  Vijai Simha  Ram Abhinav  Anuja Abhyankar  Epari Sridhar  Abhishek Mahajan  Ameya D. Puranik. Reverse swing‐M, phase 1 study of repurposing mebendazole in recurrent high‐grade glioma.cancer Medicine.https://doi.org/10.1002/cam4.3094.

4. Atanu Bhattacharjee, Vijay M Patil, Rajesh Dikshit, Kumar Prabhash, Arjun Singh, Pankaj Chaturvedi.Should we wait or not? The preferable option for patients with stage IV oral cancer in COVID-19 pandemic.Head Neck
. 2020 Jun;42(6):1173-1178. doi: 10.1002/hed.26196. Epub 2020 Apr 28.

5. Atanu Bhattacharjee, Jacinth Rajendra, Rajesh Dikshit, Shilpee Dutt.HER2 borderline is a negative prognostic factor for primary malignant breast cancer.Breast Cancer Res Treat. 2020 May;181(1):225-231. doi: 10.1007/s10549-020-05608-3.

6. Atanu Bhattacharjee.Bayesian competing risks analysis without data stratification.DOI:https://doi.org/10.1016/j.cegh.2019.08.010.

7.Akshat Malik,Sudhir Nair,Arjun Singh,Komal Lamba,Swapnil Rane,Munita Bal,Atanu Bhattacharjee,Hisham Mehanna, Pankaj Chaturvedi.Soft tissue deposit in neck dissection specimen carries a poor prognosis in oral cancer: A matched pair analysis.

8. Vanita Noronha,Vijay Maruti Patil,Amit Joshi,Manoj Mahimkar,Usha Patel,Manish Kumar Pandey,Arun Chandrasekharan,Hollis Dsouza,Atanu Bhattacharjee,Abhishek Mahajan,Nilesh Sabale,Jai Prakash Agarwal,Sarbani Ghosh-Laskar,Ashwini Budrukkar,Anil K D'Cruz,Pankaj Chaturvedi ,Prathamesh S Pai,Devendra Chaukar, Sudhir Nair,Shivakumar Thiagarajan,Shripad Banavali,Kumar Prabhash.
Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer. Oncotarget
. 2020 Jan 28;11(4):399-408. doi: 10.18632/oncotarget.27443.

9. Vanita Noronha,Atanu Bhattacharjee,Vijay M Patil,Amit Joshi,Nandini Menon,Srushti Shah,Sadhana Kannan,Sadaf A Mukadam, Kamesh Maske, Sandeep Ishi, Kumar Prabhash.Aprepitant for Cough Suppression in Advanced Lung Cancer: A Randomized Trial.Chest
. 2020 Jan 18;S0012-3692(20)30032-5. doi: 10.1016/j.chest.2019.11.048. Online ahead of print.

10. Vijay Maruti Patil,Vanita Noronha,Shivakumar Thiagarajan,Amit Joshi,Arun Chandrasekharan,Vikas Talreja,Jaiprakash Agarwal,Sarbani Ghosh-Laskar,Ashwini Budrukkar,Shashikant Juvekar,Abhishek Mahajan,Archi Agarwal,Nilendu Purandare,Atanu Bhattacharjee, Anil K D'Cruz, Pankaj Chaturvedi,Prathamesh S Pai 2,Devendra Chaukar,Kumar Prabhash.Salvage surgery in head and neck cancer: Does it improve outcomes?Eur J Surg Oncol. 2020 Jan 15;S0748-7983(20)30024-X. doi: 10.1016/j.ejso.2020.01.019.

## [2019]
1. Amit Joshi, Sameer Shrirangwar, Vanita Noronha, Nilesh Sable, Archi Agarwal, Palak Popat, Atanu Bhattacharjee, Kumar Prabhash.
 A tertiary care audit of using abiraterone acetate in patients of metastatic castrate-resistant prostate cancer.South Asian J
Cancer 2020;9:23-6.
2. Thiagarajan S, Dhar H, Bhattacharjee A, Fatehi KS, Shah SB, Chaukar D, Nair D, Deshmukh A, Prabhash K, Joshi A, Patil V, Noronha V, Laskar SG, Cruz AKD.Patterns of failure and outcomes in cT4 Oral squamous cell carcinoma (OSCC) undergoing upfront surgery in comparison to Neo-Adjuvant Chemotherapy (NACT) followed by surgery: A Matched Pair analysis.Oral Oncol. 2019 Nov 15;100:104455. doi: 10.1016/j.oraloncology.2019.104455.
3. Narasimhan M, Kannan S, Chawade A, Bhattacharjee A, Govekar R. Clinical biomarker discovery by SWATH-MS based label-free quantitative proteomics: impact of criteria for identification of differentiators and data normalization method.J Transl Med. 2019 May 31;17(1):184. doi: 10.1186/s12967-019-1937-9.
4. Patil V#1,2, Joshi A#1,2, Noronha V1,2, Agarwala V1,2, Chougule A1,2, Kanan S, Bhattacharjee A, Chandrasekharan A, Pande N, Simha V, Goud S, More S, Kumar R, Mahajan A, Janu A, Purandare N, Prabhash K.Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer.Oncotarget. 2019 Oct 29;10(59):6297-6307. doi: 10.18632/oncotarget.27214. eCollection 2019 Oct 29.
5. Singhavi HR, Chakrabarti S, Singh A, Mair M, Bhattacharjee A, Shetty R, Qayyumi B, Pai A, Joshi P, Nair D, Nair S, Chaturvedi P.Comparison of the 7th and 8th edition AJCC classification system in oral cavity squamous cell cancers.Int J Cancer. 2019 Oct 3. doi: 10.1002/ijc.32720. 
6. Vijay Patil, Vanita Noronha, Amit Joshi, Anuradha Chougule, Atanu Bhattacharjee, Alok Goel, Vikas Talreja, Nandini Menon, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash.
Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/ carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer.Cancer Research,Statistics and Treatment.2019 2(1).21-27.
7. Patil VM, Noronha V, Joshi A, Agarwal J, Ghosh-Laskar S, Budrukkar A, Murthy V, Gupta T, Mahimkar M, Juvekar S, Arya S, Mahajan A, Agarwal A, Purandare N,Rangarajan V, Balaji A, Chaudhari SV, Banavali S, Kannan S, Bhattacharjee A, D'Cruz AK, Chaturvedi P, Pai PS, Chaukar D, Pantvaidya G, Nair D, Nair S, Deshmukh A,Thiagarajan S, Mathrudev V, Manjrekar A, Dhumal S, Maske K, Bhelekar AS, Nawale K, Chandrasekharan A, Pande N, Goel A, Talreja V, Simha V, Srinivas S, Swami R,Vallathol DH, Dsouza H, Shrirangwar S,Turkar S, Abraham G, Thanky AH,Patel U,Pandey MK,Prabhash K.A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.Cancer. 2019 Sep 15;125(18):3184-3197. doi: 10.1002/cncr.32179. Epub 2019 May 31.
8. Noronha V, Patil VM, Joshi A, Menon N, Chougule A, Mahajan A, Janu A, Purandare N, Kumar R, More S, Goud S, Kadam N, Daware N, Bhattacharjee A, Shah S, Yadav A,
Trivedi V, Behel V, Dutt A, Banavali SD, Prabhash K.Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.J Clin Oncol. 2019 Aug 14:JCO1901154. doi: 10.1200/JCO.19.01154.
9. Bhattacharjee A.Bayesian competing risks analysis without data stratification.Clinical Epidemiology and Global Health (In press) 2019.
10.Mukesh Kumar  Prashant Kr. Sonker  Agni Saroj  Aanchal Jain  Atanu Bhattacharjee  Rakesh Kr. Saroj.
Cancer Reports.Parametric survival analysis using R: Illustration with lung cancer data.2019. https://doi.org/10.1002/cnr2.1210
11. Bhattacharjee A.A joint longitudinal and survival model for dynamic treatment regimes in Presence of Competing Risk Analysis.
Clinical Epidemiology and Global Health.2019.7(3).337-341.
12. Bhattacharjee A,Budukh A,Dikshit  R.Prostate cancer survival estimates: An application with piecewise hazard function derivation.South Asian journal of cancer.2019.8(3).105.
13. A Bhattacharjee, GK Vishwakarma.Time-course data prediction for repeatedly measured gene expression.International Journal of Biomathematics.2019.12(4).
14. Vijay M Patil, Arun Chandrasekharan, Dilip Harindran Vallathol, Mridul Malhotra, Ram Abhinav, Priti Agarwal, Anu Rajpurohit, Raees Tonse, Atanu Bhattacharjee, Rakesh Jalali. Antiemetic prophylaxis with temozolomide: an audit from a tertiary care center.2019.Neuro-Oncology Practice.4(19).
15. Atanu Bhattacharjee, Gaurav Roy, Atul Budukh, Rajesh Dikshit, Vijay M Patil, Amit Joshi, Vanita Noronha, Kumar Prabash, Papai Roy A competing risk analysis of death patterns in male genitourinary cancer.(2019).Cancer Reports, e1174.
## [2018]
## [2017]
## [2016]
## [2015]
### [2014]
1.Atanu BhattacharjeeDistance Correlation Coefficient: An Application with Bayesian Approach in Clinical Data Analysis.Journal of Modern Applied Statistical Methods 2014;13(1):354-366.[2014A.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4715052/2014A.pdf)

2.Atanu Bhattacharjee, and Subhradev Sen.Letter to the editor: Second, third, and fourth head and neck tumors. A progressive
decrease in survival.Head & Neck 36: 1376, 2014.[2014B.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4715056/2014B.pdf)

3.Atanu Bhattacharjee and Dilip C. Nath.Joint Longitudinal and Survival Data Modeling: An Application inAnti-Diabetes Drug Therapeutic Effect. Statistics in Transition new series.2014;15(3).437-452.
[2014C.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4715058/2014C.pdf)

### [2013]
1.Bhattacharjee Atanu,and  Saikia Hemanta.An Application of Bootstrap Regression Method in Age Dependency Structure to the Community.
Indian Journal of Public Health Research & Development.2013;4(3).44-48.[2013A.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4715108/2013A.pdf)
## [2012]
## [2011]
1.Bhattacharjee A, Bhattacharjee D. A Bayesian Approach to Compare the Statewise Dengue Death Counts in India. International Journal of Collaborative Research on Internal Medicine & Public Health. 2011; 3(10):715-723.[20200602100511.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4714786/20200602100511.pdf)

2.Dilip C. Nath and Atanu Bhattacharjee. Comparison of the tetrachoric correlation coefficients and odds in generalized estimating equation with Bayesian approach: an application in type 2 diabetes patients data.2011;5(2):97-108.
[20200602101224.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4714806/20200602101224.pdf).

3.Hemanta Saikia,Dibyojyoti Bhattacharjee,and Atanu Bhattacharjee.Is IPL responsible for cricketers’ performance in Twenty20 World Cup?
International Journal of Sports Science and Engineering.2012;6(02):096-110.[20200602102234.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4714831/20200602102234.pdf)

4.Dilip C. Nath and Atanu Bhattacharjee.Effect of Correlation Structure in Generalized Estimating Equation and Quasi Least Square: An Application in Type 2 Diabetes Patient. Pak.j.stat.oper.res.2011.VII(2).401-412.
[20200602102044.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4714821/20200602102044.pdf)

5.A Bayesian Approach for Autoregressive Models in Longitudinal Data Analysis: An Application to Type 2 Diabetes Drug Comparison.[20200602101832.pdf](https://github.com/AtanuBhattacharjee/github.io/files/4714820/20200602101832.pdf)



## Book Publication
1.Atanu Bhattacharjee (2021).Bayesian Approaches in Oncology Using R and OpenBUGS.(In press).CRC press.
2. Atanu Bhattacharjee (2013).Bayesian Analysis in Longitudinal Data. Lambert Publication.
### Chapters in Book
Gaurav Roy, Atanu Bhattacharjee, and Iqra Khan (2020).‘Essentials of Cancer Genomic,
Computational Approaches and Precision Medicine. Spinger Verlag, Nature.

### Biostatistics Tutorial
1. Introduction to Biostatistics
[1546938553M1.pdf](https://github.com/atanustat/biostatonco/files/4000779/1546938553M1.pdf)
2. Survival Analysis
[Survival Analysis.pdf](https://github.com/atanustat/biostatonco/files/4000798/Survival.Analysis.pdf)
3. Parametric survival analysis
[parametric survival analysis.pdf](https://github.com/atanustat/biostatonco/files/4000800/parametric.survival.analysis.pdf)
4. Acturial estimator with R
[Acturial estimator with R.pdf](https://github.com/atanustat/biostatonco/files/4000801/Acturial.estimator.with.R.pdf)
5. Kaplan Meier Estimators-I
[Kaplan Meier Estimators-I.pdf](https://github.com/atanustat/biostatonco/files/4000802/Kaplan.Meier.Estimators-I.pdf)
6. Kaplan Meier Estimators-II
[Uploading Kaplan Meier Estimators-Ii.pdf…]()
7. Nelson aalen estimator
[nelson aalen estimator.pdf](https://github.com/atanustat/biostatonco/files/4001281/nelson.aalen.estimator.pdf)
8. Equality of survival
[equality of survival function.pdf](https://github.com/atanustat/biostatonco/files/4001282/equality.of.survival.function.pdf)
9. Mantel Haenszel Estimator
[Mantel-Haenszl Estimators.pdf](https://github.com/atanustat/biostatonco/files/4001284/Mantel-Haenszl.Estimators.pdf)
10. Cox PH Model
[Cox PH model.pdf](https://github.com/atanustat/biostatonco/files/4001285/Cox.PH.model.pdf)

11. Estimation and Inference for Cox’s [Estimation and Inference for Cox’s.pdf](https://github.com/atanustat/biostatonco/files/4001298/Estimation.and.Inference.for.Cox.s.pdf)
12. Diagnostics for Cox’s PH model [Diagnostics for Cox’s PH model.pdf](https://github.com/atanustat/biostatonco/files/4001299/Diagnostics.for.Cox.s.PH.model.pdf)
13. The Accelerated Failure Time [The Accelerated Failure Time.pdf](https://github.com/atanustat/biostatonco/files/4001300/The.Accelerated.Failure.Time.pdf)
14. Competing Risks Model [Competing Risks Model.pdf](https://github.com/atanustat/biostatonco/files/4001301/Competing.Risks.Model.pdf)
15. Clinical Trials [Clinical Trials.pdf](https://github.com/atanustat/biostatonco/files/4001302/Clinical.Trials.pdf)
16. Sample size determination
[sample size determination.pdf](https://github.com/atanustat/biostatonco/files/4001312/sample.size.determination.pdf)
17. Random Allocation
[random allocation.pdf](https://github.com/atanustat/biostatonco/files/4001314/random.allocation.pdf)
18. Sequential Clinical Trial-I
[sequential clinical trial.pdf](https://github.com/atanustat/biostatonco/files/4001315/sequential.clinical.trial.pdf)
19. Sequential Clinical Trial-II
[sequential clinical trial II.pdf](https://github.com/atanustat/biostatonco/files/4001316/sequential.clinical.trial.II.pdf)
20. Sequential Clinical Trial-III
[sequential clinical trial III.pdf](https://github.com/atanustat/biostatonco/files/4001318/sequential.clinical.trial.III.pdf)
21. Randomize play the winder rule
[Randomize play the winder rule.pdf](https://github.com/atanustat/biostatonco/files/4001329/Randomize.play.the.winder.rule.pdf)
22. The Play the Winnder Rule [The Play the Winnder Rule.pdf](https://github.com/atanustat/biostatonco/files/4001331/The.Play.the.Winnder.Rule.pdf)
23. Crossover Trial[Crossover trial.pdf](https://github.com/atanustat/biostatonco/files/4001332/Crossover.trial.pdf)
24. Introduction to Epidemiology[Introduction to Epidemiology.pdf](https://github.com/atanustat/biostatonco/files/4001333/Introduction.to.Epidemiology.pdf)
25. Disease Frequency[Disease Frequency-I.pdf](https://github.com/atanustat/biostatonco/files/4001335/Disease.Frequency-I.pdf)
26. Disease Frequency-II[Disease Frequency-II.pdf](https://github.com/atanustat/biostatonco/files/4001354/Disease.Frequency-II.pdf)
27. Disease Frequency-III[Disease Frequency-III.pdf](https://github.com/atanustat/biostatonco/files/4001358/Disease.Frequency-III.pdf)
28. Observational Study[Observational Study.pdf](https://github.com/atanustat/biostatonco/files/4001360/Observational.Study.pdf)
29. Analystical Study[Analytical Study.pdf](https://github.com/atanustat/biostatonco/files/4001353/Analytical.Study.pdf)
30. Case Control Study[Case Control Study.pdf](https://github.com/atanustat/biostatonco/files/4001352/Case.Control.Study.pdf)
31. Cohort Study-I [Cohort Study -I.pdf](https://github.com/atanustat/biostatonco/files/4001350/Cohort.Study.-I.pdf)
32. Cohort Study-II [Cohort Study-II.pdf](https://github.com/atanustat/biostatonco/files/4001349/Cohort.Study-II.pdf)
33.  Case Control Study -I[case Control Study -I.pdf](https://github.com/atanustat/biostatonco/files/4001346/case.Control.Study.-I.pdf)
34.  Case Control Study -II[Case Control Study II.pdf](https://github.com/atanustat/biostatonco/files/4001343/Case.Control.Study.II.pdf)
35. Confounding[confounding.pdf](https://github.com/atanustat/biostatonco/files/4001342/confounding.pdf)
36. Stratified Analysis[Stratified Analysis.pdf](https://github.com/atanustat/biostatonco/files/4001340/Stratified.Analysis.pdf)
37. Matched Analysis-I[Matched Analysis-I.pdf](https://github.com/atanustat/biostatonco/files/4001337/Matched.Analysis-I.pdf)
38.  Matched Analysis-I[Mathced Analysis-II.pdf](https://github.com/atanustat/biostatonco/files/4001336/Mathced.Analysis-II.pdf)



### Talk
1. Lung Cancer Update 2019 [presentation.pdf](https://github.com/atanustat/biostatonco/files/4002993/presentation.pdf).
2. Computational Biostatistics and Survival Analysis Talk[cce presentation.pdf](https://github.com/atanustat/biostatonco/files/4002995/cce.presentation.pdf).
### Talk on “Mathematical Sciences for Practicing 1. Hands on Survival Analysis Researchers”
(https://github.com/atanustat/biostatonco/files/4710190/AB1011.Hands.on.Survival.Analysis.pdf)







### Contact
abhattacharjee@actrec.gov.in/atanustat@gmail.com   

Centre for Cancer Epidemiology, Tata Memorial Centre, Navi Mumbai,India


